Patients Characteristics1
Patients receiving Voraxaze® with:
- No pre-existing grade 4 toxicity before Voraxaze® administration
- The appropriate increase in leucovorin rescue within 3 days after the start of HDMTX infusion
Administration of Voraxaze®
- ≤ 96 hours after HDMTX exposure, n = 64
- 96 hours after HDMTX exposure, n = 11
Inclusion Criteria1
Patients with MTX-included nephrotoxicity and delayed MTX excretion were eligible for treatment with Voraxaze®, if either of the following two conditions were met:
- Plasma MTX concentration was ≥10 μmol/L ≥42 hours after the start of HDMTX infusion
- sCr was ≥1.5 times the upper limit of normal or CrCl was ≤ 60mL/min/m2 and the plasma MTX concentration was ≥2 standard deviations above the mean ≥12 hours after MTX administration
Abbreviations: CrCl, creatinine clearance; HDMTX, high dose methotrexate; MTX, methotrexate; sCr, serum creatinine.
